**Chapter 11**

*Management of Dyslipidemia*

[15] Fujimoto J, Pitris C,

2000;2(1-2):9-25.

2014;64(21):2207-2217.

Boppart S, Brezinski M. Optical Coherence Tomography: An Emerging Technology for Biomedical Imaging and Optical Biopsy. Neoplasia.

to Intensive Statin Therapy. Diabetes.

2019;68(Supplement 1):457-P.

[22] Demircelik M, Yilmaz O, Gurel O, Selcoki Y, Atar I, Bozkurt A et al. Epicardial adipose tissue and pericoronary fat thickness measured with 64-multidetector computed tomography: potential predictors of the severity of coronary artery disease.

Clinics. 2014;69(6):388-392.

[16] Komukai K, Kubo T, Kitabata H, Matsuo Y, Ozaki Y, Takarada S et al. Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary Atherosclerotic Plaque as Assessed by Optical Coherence Tomography. Journal of the American College of Cardiology.

[17] Budoff M, Bhatt D, Kinninger A, Lakshmanan S, Muhlestein J, Le V et al. Effect of icosapent ethyl on progression

[18] Bhatt D, Steg P, Miller M, Brinton E,

Hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11-22.

[19] Nicholls S, Puri R, Anderson T, Ballantyne C, Cho L, Kastelein J et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. JAMA. 2016;316(22):2373.

[20] Ikegami Y, Inoue I, Inoue K, Shinoda Y, Iida S, Goto S et al. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. npj Aging and Mechanisms of Disease. 2018;4(1).

[21] HIRAI A, FUJIMURA K, HIRAI K, KONDO S, SHIRAKAMI A, SAKAI T et al. 457-P: One-Year Administration of Anti-PCSK9 Antibody Is Enough to Stabilize Vulnerable Coronary Plaques in Diabetic Patients, which Are Resistant

of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. European Heart Journal. 2020;41(40):3925-3932.

Jacobson T, Ketchum S et al. Cardiovascular Risk Reduction with Icosapent Ethyl for

**142**
